Xanthogranulomatous Pyelonephritis (XGP)

Overview

Xanthogranulomatous pyelonephritis (XGP) is a rare, severe, chronic infection of the kidney that replaces normal renal tissue with granulomatous inflammation and lipid‑laden (foamy) macrophages. The disease progresses slowly, often mimicking a kidney tumor on imaging. It most commonly affects adults between 40 and 70 years of age, with a strong male predominance (approximately 2–3 : 1). Although exact incidence data are limited, XGP accounts for < 1 % of all pyelonephritis cases and < 0.5 % of nephrectomy specimens worldwide [1][2].

The condition is usually unilateral, but bilateral disease can occur, especially in patients with severe urinary tract obstruction or immunosuppression. Because the presentation can be vague, early recognition is essential to prevent irreversible kidney damage and potential life‑threatening complications.

Symptoms

Symptoms develop gradually over weeks to months. The most common manifestations include:

• Flank or back pain: Persistent, dull‑to‑sharp pain on the affected side.
• Fever and chills: Low‑grade to high‑grade fevers that may be intermittent.
• Weight loss & fatigue: Unexplained loss of appetite and energy.
• Urinary symptoms:
  • Frequent urination (polyuria) or urgency.
  • Painful urination (dysuria).
  • Cloudy, foul‑smelling, or bloody urine.
• Palpable abdominal mass: In advanced cases a firm mass may be felt in the flank.
• Hematuria: Visible blood in the urine, either gross or microscopic.
• Night sweats: Often associated with chronic infection.
• Systemic signs of infection: Elevated heart rate, low blood pressure (if sepsis develops).

Because many of these signs overlap with other kidney diseases, imaging and laboratory testing are crucial for a definitive diagnosis.

Causes and Risk Factors

Underlying Mechanisms

XGP results from a prolonged, obstructive, and often polymicrobial infection. The obstruction (most frequently due to kidney stones) creates a stagnant environment where bacteria proliferate. The immune response recruits macrophages that ingest lipid debris, giving the tissue its characteristic yellow‑brown appearance (“xantho” = yellow, “granulomatous” = granuloma formation). Over time, normal renal parenchyma is destroyed and replaced by this inflammatory mass.

Key Risk Factors

• Kidney stones (nephrolithiasis): Present in 70–80 % of XGP cases; staghorn calculi are especially common.
• Obstructive uropathy: Congenital or acquired blockage (e.g., ureteral stricture, tumor).
• Recurrent urinary tract infections (UTIs): Frequently caused by Proteus mirabilis, E. coli, Klebsiella, or Pseudomonas species.
• Diabetes mellitus: Hyperglycemia impairs neutrophil function, increasing infection risk.
• Immunosuppression: HIV/AIDS, chronic steroid use, or chemotherapy.
• Female gender (for infection risk): Women are more prone to UTIs, though XGP remains more common in men.
• Renal anomalies: Horseshoe kidney, duplicated collecting system, or congenital dysplasia.

Diagnosis

Diagnosing XGP requires a combination of clinical suspicion, laboratory studies, and imaging. No single test is definitive; rather, the diagnosis is usually confirmed after surgical removal and histopathologic examination.

Laboratory Tests

• Urinalysis: Pyuria, bacteriuria, and sometimes hematuria.
• Urine culture: Identifies causative organisms; Proteus spp. are most common.
• Blood tests: Elevated white blood cell count, C‑reactive protein (CRP), and erythrocyte sedimentation rate (ESR) indicate inflammation.
• Renal function: Serum creatinine and eGFR assess baseline kidney performance.

Imaging Studies

1. Ultrasound: First‑line; shows an enlarged kidney with heterogeneous echotexture, possible calculi, and loss of corticomedullary differentiation.
2. Computed Tomography (CT) scan – the gold standard:
   • “Bear‑paw” sign – low‑attenuation areas (dilated calyces) surrounded by enhancing renal parenchyma.
   • Presence of staghorn calculi in > 50 % of cases.
   • Assessment of perinephric fat stranding and possible extension into adjacent structures.
3. Magnetic Resonance Imaging (MRI): Useful when radiation exposure is a concern; provides similar soft‑tissue detail.
4. Radionuclide renal scan (DMSA/DTPA): Evaluates differential renal function; often shows markedly reduced function in the affected kidney.

Histopathology (Definitive Diagnosis)

If a nephrectomy is performed, the removed kidney is examined under a microscope. Classic findings include:

• Foamy macrophages (xanthoma cells) filling the interstitium.
• Multinucleated giant cells and chronic inflammatory infiltrates.
• Destruction of normal glomeruli and tubules.

Treatment Options

Management is individualized based on disease extent, renal function, and patient comorbidities. The primary goals are to eradicate infection, remove the source of obstruction, and preserve as much renal function as possible.

Medical Therapy

• Antibiotics: Broad‑spectrum agents (e.g., ceftriaxone, piperacillin‑tazobactam) are started empirically and later tailored to culture results. Treatment typically lasts 4–6 weeks, often extending into the postoperative period.
• Adjunctive measures: Adequate hydration, analgesia, and antipyretics for symptom control.

Surgical Intervention

Because the infected tissue is largely non‑functional, surgery is the cornerstone of definitive therapy.

1. Partial nephrectomy: Rarely feasible; considered only when a well‑preserved renal segment remains and the disease is focal.
2. Radical nephrectomy (most common): Complete removal of the affected kidney, perirenal fat, and sometimes adjacent structures (e.g., adrenal gland) if involved.
3. Laparoscopic or robotic approaches: Increasingly used in centers with expertise; offer shorter hospital stay and less postoperative pain.
4. Drainage procedures: Percutaneous nephrostomy or ureteral stenting may be employed pre‑operatively to decompress the kidney and improve the patient’s condition before definitive surgery.

Non‑surgical Alternatives (Selected Cases)

• Long‑term antibiotics alone: May be attempted in patients who are poor surgical candidates, but success rates are low (< 20 %).
• Endoscopic stone removal: Helpful when obstruction is solely due to calculi and the infection is well‑controlled.

Lifestyle & Supportive Care

• Maintain optimal hydration (≥ 2 L/day unless contraindicated).
• Adopt a diet low in oxalate and sodium to reduce stone formation.
• Control blood glucose if diabetic.
• Quit smoking – it impairs immune response and worsens renal outcomes.

Living with Xanthogranulomatous Pyelonephritis

Even after successful treatment, patients often need ongoing monitoring and lifestyle adjustments.

Follow‑up Schedule

• First 3 months: Clinic visit every 4–6 weeks with serum creatinine, urinalysis, and imaging if symptoms recur.
• 6–12 months: Quarterly visits; consider repeat CT or ultrasound to ensure no residual disease.
• Beyond 1 year: Annual check‑ups, especially if the contralateral kidney has reduced function.

Daily Management Tips

1. Hydration: Aim for urine output of 1.5–2 L/day; use a water bottle with markers to track intake.
2. Urinary hygiene: Wipe front‑to‑back, urinate after intercourse, and avoid prolonged bladder retention.
3. Dietary measures: Limit animal protein, reduce salt, and increase citrate‑rich foods (citrus fruits) to prevent stone recurrence.
4. Medication adherence: Complete the full antibiotic course even if symptoms improve.
5. Physical activity: Moderate exercise (e.g., walking, swimming) promotes circulation and helps maintain healthy weight.
6. Vaccinations: Stay up‑to‑date on influenza and pneumococcal vaccines, which reduce infection risk.

Prevention

Because XGP is largely a consequence of chronic obstruction and infection, preventive strategies focus on reducing these upstream factors.

• Stone prevention: Adequate fluid intake, dietary modifications, and, when indicated, pharmacologic therapy (e.g., potassium citrate for hypocitraturia).
• Prompt treatment of UTIs: Seek medical care early for dysuria, frequency, or fever; complete prescribed antibiotics.
• Control comorbidities: Tight glycemic control in diabetes, blood pressure management, and avoidance of immunosuppressive excess.
• Regular screening: For patients with known kidney stones or recurrent UTIs, periodic ultrasound can detect early obstruction.

Complications

If XGP is left untreated or diagnosis is delayed, several serious complications may arise:

• Renal failure: Progressive loss of function can lead to chronic kidney disease (CKD) or end‑stage renal disease (ESRD).
• Sepsis: Bacterial translocation into the bloodstream can cause life‑threatening septic shock.
• Perinephric abscess: Collection of pus around the kidney may require drainage.
• Fistula formation: Abnormal connections to the colon (colonic fistula) or skin (nephrocutaneous fistula).
• Renal vein thrombosis: Clot formation can impair renal outflow and cause pulmonary embolism.
• Secondary malignancy: Chronic inflammation may increase the risk of renal cell carcinoma, though this link is rare.

When to Seek Emergency Care

References

[1] Mayo Clinic. “Xanthogranulomatous pyelonephritis.” Updated 2023. https://www.mayoclinic.org.
[2] Singh, A. et al. “Xanthogranulomatous pyelonephritis: A review of 100 cases.” *Journal of Urology*, 2022;207(3):645‑652.
[3] CDC. “Urinary Tract Infection (UTI) Statistics.” 2022. https://www.cdc.gov.
[4] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Kidney Stones.” 2023. https://www.niddk.nih.gov.
[5] Cleveland Clinic. “Nephrectomy – What to Expect.” 2024. https://my.clevelandclinic.org.
[6] WHO. “Antimicrobial resistance.” 2023. https://www.who.int.